Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $11.23 and traded as low as $10.65. Innovent Biologics shares last traded at $10.65, with a volume of 1,620 shares changing hands.
Innovent Biologics Price Performance
The firm has a 50-day moving average of $12.49 and a two-hundred day moving average of $11.23.
Innovent Biologics Company Profile
Innovent Biologics, Inc is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of medicines for cancer, autoimmune diseases and metabolic disorders. The company develops biologic therapies, including monoclonal antibodies, antibody-drug conjugates and other advanced treatments, with the goal of providing innovative and more accessible medicines.
Its marketed portfolio includes sintilimab, an immunotherapy developed in collaboration with Eli Lilly and marketed in China under the brand name Tyvyt, as well as biosimilar and biologic products for oncology and immune-related conditions.
See Also
- Five stocks we like better than Innovent Biologics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
